The use of sacubitril/valsartan was beneficial in treating heart failure patients due to reduced ejection fraction when compared with enalapril, according to PARADIGM-HF trial results presented at ACC.17. Sacubitril/valsartan was associated with a reduction in CV death and hospitalization for heart failure and a slowed progression of heart failure. Read more >>>